Patients with multiple myeloma who received idecabtagene vicleucel, popularly known as "ide-cel," a chimeric antigen receptor (CAR) T-cell treatment, had no difference in overall survival outcomes regardless of race or ethnicity.
According to a study published in Blood Advances, patients with multiple myeloma who received idecabtagene vicleucel, also known as "ide-cel," a chimeric antigen receptor (CAR) T-cell treatment, exhibited no change in overall survival outcomes regardless of race or ethnicity.
Swedish researchers have developed a microscale device for implantation in the eye, opening up new possibilities for cell-based treatment of diabetes and other disorders.
Cancer-related tiredness (CRF) is a crippling yet all-too-common disease that has a negative impact on patients' quality of life while they are receiving treatment. There are currently no viable pharmaceutical therapies available for the constellation of symptoms that together constitute CRF
Pharma company Cipla has launch its drone-based deliveries of its critical medicines (cardiac, respiratory, and other essential chronic therapies) for hospitals and pharmacies in Himachal Pradesh in partnership with Sky Air Mobility.
Researchers from the Johns Hopkins Malaria Research Institute at the Johns Hopkins Bloomberg School of Public Health have made an important discovery about Aedes aegypti mosquitos, which could one day lead to better methods for reducing mosquito-to-human transmission of dengue, yellow fever,
According to a study conducted by scientists at Weill Cornell Medicine, the vertebral bones that make up the spine originate from a special kind of stem cell that secretes a protein that encourages tumour metastasis. The finding opens up a new area of study into spinal illnesses, sheds light
Researchers found that identifying and analysing the volatile organic chemicals in individuals' exhaled breath who had malignant pleural mesothelioma showed promise as a screening tool for MPM.
The innovative device, which is the size and shape of a grain of rice, can perform hundreds of studies at the same time to examine the impact of novel treatments on some of the most difficult-to-treat brain tumours.
Researchers from Brigham and Women's Hospital, a founding member of the Mas
Now, a team led by Assistant Professor Yasuro Furuichi from Tokyo Metropolitan University have emerged with a key part of the puzzle. In previous work, they found that Musashi-2 (Msi2), a protein originally discovered in nerve cells, was also expressed in skeletal muscle tissue.
searchers who previously developed the first 3D human cell culture models of Alzheimer's disease (AD) that exhibit two major hallmarks of the condition—the generation of amyloid beta deposits followed by tau tangles—have now used their model to investigate whether the exercise-induced muscle